Article Abstract

Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing

Authors: Yuki Matsumura, Yuki Owada-Ozaki, Hiroyuki Suzuki


Randomized clinical trials have demonstrated the positive effects of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for patients with advanced or recurrent lung adenocarcinomas harboring EGFR gene mutations (1-3). Detecting cancer-specific gene mutations and exploring their targeted therapies for advanced non-small cell lung cancer (NSCLC) have therefore become a major topic of discussion over the past decade.